HepG2 Cell Line Producing Hepatitis B Virus, Genotype B2

Catalog No. NR-56529

This reagent is the tangible property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

T. Jake Liang, Ph.D., Chief of Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Bethesda, Maryland, USA

Manufacturer:

BEI Resources

Product Description:

HepG2 cell line producing hepatitis B virus (HBV), genotype B2 (HepG2-GtB2) is a stable cell line designed by transfecting plasmids with an insert of replicon-competent 1.3x length HBV, genotype B2 genome and a hygromycin marker into HepG2 cells capable of HBV replication. HepG2-GtB2 can be passaged *in vitro* and *in vivo* for functional and biological studies.[1]

Material Provided:

Each vial contains approximately 1 mL of cell culture suspension frozen in freeze medium [80% Dulbecco's MEM (DMEM); 10% fetal bovine serum (FBS) and 10% dimethylsulfoxide (DMSO) cryopreservative]. Sufficient cells are provided to initiate at least one new culture. The cell count, expressed as cells per vial, is shown on individual Certificates of Analysis for each lot.

Packaging/Storage:

NR-56529 was packaged aseptically in screw-capped plastic cryovials. The product should be stored at -100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer. Storage at -70°C will result in loss of viability.

Note: Do not under any circumstances store vials at temperatures warmer than -100°C. Storage under these conditions will result in the death of the culture.

To ensure the highest level of viability, the vial should be thawed, and the culture initiated as soon as possible upon receipt. Any warming of the product during shipping and transfer must be avoided, as this will adversely affect the viability of the product after thawing. For transfer between freezers and shipping, the cells may be placed on dry ice for brief periods, although use of a portable liquid nitrogen carrier is preferred. Please read the following recommendations prior to reconstituting this material.

Safety Precautions:

When handling frozen vials, it is highly recommended that protective gloves, lab coat and full-face mask be worn. Even brief exposure to the ultra-cold temperature can cause tissue damage from frostbite. Also, some vials may slowly fill with liquid nitrogen if they have been immersed during cryogenic storage. When thawing, the liquid nitrogen may rapidly expand as it changes to gas, breaking the vial or cap with explosive force, sending debris flying with enough velocity to cause injury. Store and use in areas with adequate ventilation.

Thawing and Growth:

Note: Extended incubation and sub-culturing may be required to produce sufficient cells for downstream applications.

Prior to thawing the cells, prepare cell growth media (CGM), with and without hygromycin B (refer to Appendix I and II). The CGMs are formulated for use in an aerobic atmosphere with 5% CO_2.

Rapidly thaw the vial of cells in a 37°C water bath. To reduce the risk of contamination, keep the cap and O-ring of the vial out of the water and repeatedly check the cap for tightness during thawing. Remove from the water bath immediately when thawed. Dry the vial with a sterile wipe, decontaminate using a wiper soaked with 70% isopropyl alcohol and let the vial air dry. Aseptically open the vial, remove the vial contents and add to a centrifuge tube containing 4 mL of CGM without antibiotic. Centrifuge the cell suspension at 125 × g for 8 to 10 minutes at 18°C to 25°C. Discard the supernatant and resuspend the cell pellet in 10 mL of pre-warmed CGM without antibiotic. Transfer the cell suspension into a 75 cm^2 tissue culture flask. Incubate the new culture at 37°C in an aerobic atmosphere with 5% CO_2 for 48 hours, then remove the CGM without antibiotic and replace with an equal amount of CGM with hygromycin B.

Sub-culture procedure:
After trypsinizing the monolayer using standard methods, aseptically transfer the contents of the flask to a centrifuge tube containing an equal volume of CGM without antibiotic. Centrifuge the cell suspension at 125 × g for 8 to 10 minutes at 18°C to 25°C. Discard the supernatant and resuspend the cell pellet in an equal amount as the original volume of pre-warmed CGM without antibiotic. Add cell suspension to as many 75 cm^2 tissue culture flasks as needed at a sub-cultivation ratio of 1:2 to 1:4 (a seeding density of 4×10^4 to 6×10^4 cells/cm^2 is recommended). Incubate the new culture at 37°C in an aerobic atmosphere with 5% CO_2 for 48 hours, then remove the CGM without antibiotic and replace with an equal amount of CGM with hygromycin B.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: HepG2 Cell Line Producing Hepatitis B Virus, Genotype B2, NR-56529."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use, and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure the authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers, and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, and non-commercial purposes only. This material, its product, or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products, or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Zhang, M., et al. “Infection Course, Virological Features and IFN-α Responses of HBV Genotypes in Cell Culture and Animal Models.” J. Hepatol. 75 (2021): 1335-1345. PubMed: 34363922.

Support Provided by NIAID

Appendix I: Cell Growth Medium without Antibiotic for Cell Line Initialization (First 48 hours)

DMEM	90%
FBS	10%

Appendix II: Cell Growth Medium with Hygromycin B for Cell Line Maintenance

DMEM	90%
FBS	10%
Hygromycin B	500 µg/mL

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898